Mitochondrial Replacement Techniques: Ethical, Social, and Policy Considerations

Public Discussion Meeting

Monday, March 21, 2016

National Academy of Sciences Building
Lecture Room
2101 Constitution Avenue, N.W.
Washington, DC

Background and Meeting Objectives:

• On February 3, 2016 the IOM publicly released the report, *Mitochondrial Replacement Techniques: Ethical, Social, and Policy Considerations*, in which it is concluded that it is ethically permissible to conduct clinical investigations of mitochondrial replacement techniques (MRT), subject to certain conditions and principles laid out in the report.

• The objectives of this meeting are:
  o Discuss the report’s findings, conclusions, and recommendations.
  o Hear a range of perspectives and reactions to the report and provide a venue for open dialogue.

1:30 p.m.  FDA Perspective

_Celia Witten_, Director, Office of Cellular, Tissue, and Gene Therapy, CBER/FDA

1:45 p.m.  Overview of Committee’s Report

_Jeffrey Kahn_, Committee Chair, Johns Hopkins University
_Marni Falk_, Committee Member, University of Pennsylvania and The Children’s Hospital of Philadelphia
_James Childress_, Committee Member, University of Virginia
_R. Alta Charo_, Committee Member, University of Wisconsin - Madison

2:10 p.m.  Q&A/Discussion

3:00 p.m.  Adjourn